A detailed history of Rafferty Asset Management, LLC transactions in Ardelyx, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 594,455 shares of ARDX stock, worth $3.06 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
594,455
Previous 642,711 7.51%
Holding current value
$3.06 Million
Previous $4.76 Million 14.01%
% of portfolio
0.01%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$5.28 - $7.57 $254,791 - $365,297
-48,256 Reduced 7.51%
594,455 $4.1 Million
Q2 2024

Aug 13, 2024

SELL
$5.89 - $9.31 $2.43 Million - $3.84 Million
-412,582 Reduced 39.1%
642,711 $4.76 Million
Q1 2024

May 13, 2024

SELL
$6.05 - $9.74 $1.94 Million - $3.12 Million
-320,221 Reduced 23.28%
1,055,293 $7.7 Million
Q4 2023

Feb 13, 2024

BUY
$3.29 - $6.64 $913,369 - $1.84 Million
277,620 Added 25.29%
1,375,514 $8.53 Million
Q3 2023

Nov 13, 2023

SELL
$3.3 - $4.83 $3.26 Million - $4.78 Million
-989,230 Reduced 47.4%
1,097,894 $4.48 Million
Q2 2023

Aug 11, 2023

BUY
$3.23 - $4.95 $1.74 Million - $2.67 Million
538,992 Added 34.82%
2,087,124 $7.08 Million
Q1 2023

May 11, 2023

BUY
$2.68 - $4.79 $4.15 Million - $7.42 Million
1,548,132 New
1,548,132 $7.42 Million
Q3 2021

Nov 10, 2021

SELL
$1.27 - $8.17 $354,780 - $2.28 Million
-279,355 Closed
0 $0
Q2 2021

Aug 10, 2021

BUY
$6.55 - $8.98 $738,597 - $1.01 Million
112,763 Added 67.69%
279,355 $2.12 Million
Q1 2021

May 10, 2021

BUY
$6.1 - $7.69 $915,707 - $1.15 Million
150,116 Added 911.12%
166,592 $1.1 Million
Q4 2020

Feb 10, 2021

SELL
$5.05 - $7.1 $202,934 - $285,313
-40,185 Reduced 70.92%
16,476 $107,000
Q3 2020

Nov 13, 2020

BUY
$5.25 - $7.08 $137,292 - $185,149
26,151 Added 85.71%
56,661 $297,000
Q2 2020

Aug 07, 2020

BUY
$5.37 - $8.11 $163,838 - $247,436
30,510 New
30,510 $211,000

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $796M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.